Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a ...

Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...